Archive for December, 2008

Market Wire - New Study Suggests Cymbalta(R) Reduced Depression Symptoms at Least as Fast as a Leading Competitor

Wednesday, December 31st, 2008

Cymbalta (duloxetine hydrochloride)
reduced symptoms of depression at least as fast as Lexapro
(escitalopram) by the end of two weeks, according to results from the first
head-to-head study comparing the two antidepressants. The results were
released by Eli Lilly and Company (NYSE: LLY) at a meeting of a major
scientific society.

In this eight-week study, Cymbalta, a serotonin and norepinephrine reuptake
i…

Clinical Psychiatry News - Lilly warned on Cymbalta

Sunday, December 28th, 2008

A promotional brochure mailed to physicians on Cymbalta (duloxetine) delayed-release capsules overstates the drug’s efficacy and “omits some of the most serious and important risk information associated with its use,” said the Food and Drug Ad…

Chain Drug Review - Cymbalta contract

Saturday, December 27th, 2008

Eli Lilly and Co. and Boehringer Ingelheim GmbH have agreed to commercialize Cymbalta for the treatment of depression in countries outside the United States (excluding Japan). Lilly anticipates that it will make a European submission for the product this year.

Relat…

Chain Drug Review - Cymbalta found safe as nerve pain treatment

Saturday, December 20th, 2008

Cymbalta has been found safe and well-tolerated as a drug treatment for diabetic nerve pain. The study in the Journal of Palliative Medicine also concludes that the Eli Lilly & Co. product does not adversely affect the progression of diabetes or such complications as damage to the nerves, kidneys and eyes.

Re…

Philadelphia Inquirer, The - Wyeth says heart–drug competition was surprise

Monday, December 15th, 2008

THE FDA SAYS development of a potentially life-threatening serotonin syndrome may occur in treatment with four selective serotonin reuptake inhibitors: Lilly’s Cymbalta (duloxetine HCl) delayed release capsules, Wyeth’s Effexor (venlafaxine HCL) tablets and Effexor extended release capsules, Lilly’s Prozac (fluoxetine capsules and oral solution) and Lilly’s Symbyax (olanzapine and fluoxetine HCL capsules).

Most Popular
10 Jobs That Pay $30 An Hour
E…

Market Wire - New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression

Tuesday, December 9th, 2008

New data suggest that patients with
fibromyalgia treated with 60mg or 120mg of Cymbalta (duloxetine HCl)
experienced greater reduction in pain severity beginning one week after
starting duloxetine than those taking placebo (sugar pill), as measured by
the Brief Pain Inventory Average Pain Score (BPI). The study, which
incl…

PR Newswire - Patients Taking Cymbalta® Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study

Saturday, December 6th, 2008

Patients on Treatment Also Experienced Improved Physical Functioning
INDIANAPOLIS, June 13 /PRNewswire-FirstCall/ — New data suggest that patients with osteoarthritis pain of the knee treated with 60 mg and 120 mg Cymbalta (duloxetine HCl) on…

Medical Marketing and Media - ELI LILLY AND CO. HELD

Tuesday, December 2nd, 2008

ELI LILLY AND CO. HELD its 10th Annual Welcome Back Awards May 3 in Washington, DC. The awards honor individuals for outstanding commitments to mental health. Through them, Lilly has donated nearly $500,000 to nonprofits. This year’s winners included Rory White (at right), founding manager of LA’s Skid Row Lamp Art Project, who was named Welcome…

Harvard Mental Health Letter - Questions & Answers.

Monday, December 1st, 2008

Q. Does the new antidepressant duloxetine (Cymbalta) have any advantages over other antidepressant drugs?
A. Duloxetine (Cymbalta) became available by prescription in the summer of 2004. Described as a selective serotonin and norepinephrine reuptake inhibitor (SSNRI), it boosts the activity of two neurotransmitters that play a r…